Scarica l'app Stockscreener
3.70
2.63%
-0.10
Dopo l'orario di chiusura:
3.68
-0.02
-0.54%
Precedente Chiudi:
$3.80
Aprire:
$3.8
Volume 24 ore:
186.02K
Relative Volume:
1.11
Capitalizzazione di mercato:
$20.03M
Reddito:
-
Utile/perdita netta:
$-21.21M
Rapporto P/E:
-0.1135
EPS:
-32.6
Flusso di cassa netto:
$-16.86M
1 W Prestazione:
-9.98%
1M Prestazione:
+0.00%
6M Prestazione:
-12.74%
1 anno Prestazione:
-17.59%
Intervallo 1D:
$3.66
$3.88
Intervallo di 1 settimana:
$3.66
$4.40
Portata 52W:
$3.02
$6.01
Cingulate Inc Stock (CING) Company Profile
Nome
Cingulate Inc
Settore
Industria
Telefono
(913) 942-2300
Indirizzo
1901 W. 47TH PLACE, KANSAS CITY
Confronta CING con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
3.70 | 21.30M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | ROTH MKM | Buy |
| 2023-12-22 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Borsa (CING) Ultime notizie
Backtesting results for Cingulate Inc. Equity Warrant trading strategiesInsider Selling & Stepwise Trade Execution Plans - newser.com
Can Cingulate Inc. stock deliver consistent earnings growthJuly 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Will Cingulate Inc. stock gain from government policies2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
What institutional flow reveals about Cingulate Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
Will Cingulate Inc. stock remain a Wall Street favoriteTrade Signal Summary & Safe Entry Zone Identification - newser.com
Using portfolio simulators with Cingulate Inc. Equity Warrant includedTrade Entry Report & Entry Point Strategy Guides - newser.com
How Cingulate Inc. stock compares to industry benchmarksTrade Risk Assessment & High Conviction Buy Zone Alerts - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock bottoming outJuly 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success - TipRanks
How supply chain issues affect Cingulate Inc. stock2025 Investor Takeaways & Expert Verified Movement Alerts - newser.com
Why Cingulate Inc. stock could be next big winnerJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Does Cingulate Inc. fit your quant trading modelMarket Rally & Smart Investment Allocation Tips - newser.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review Retail Bets On Buyout Potential - Menafn.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - Asianet Newsable
Will Cingulate Inc. continue its uptrendJuly 2025 Earnings & Long-Term Safe Return Strategies - newser.com
FDA accepts Cingulate’s ADHD drug application, sets May 2026 target date - Investing.com Canada
What’s next for Cingulate Inc. stock priceJuly 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Cingulate receives target date for when it could receive FDA approval - The Business Journals
Cingulate Inc’s NDA for CTx-1301 Accepted by FDA - TipRanks
Cingulate announces FDA accepted for review the NDA for CTx-1301 - TipRanks
Cingulate Inc FDA Accepts NDA for CTx-1301 for ADHD - TradingView
FDA Accepts Cingulate’s New Drug Application for CTx-1301 - GlobeNewswire
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date - Yahoo Finance
Will Cingulate Inc. bounce back from current support2025 Retail Activity & Verified Entry Point Signals - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
How Cingulate Inc. Equity Warrant stock trades before earningsWatch List & Daily Market Momentum Tracking - newser.com
Is it too late to sell Cingulate Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - newser.com
Is Cingulate Inc a good long term investmentREITs Market Trends & Rapid Portfolio Strategies - earlytimes.in
Cingulate Inc. (NASDAQ:CING) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Is Cingulate Inc. stock entering bullish territoryCEO Change & Smart Money Movement Alerts - newser.com
Analyzing drawdowns of Cingulate Inc. Equity Warrant with statistical tools2025 Year in Review & Stock Timing and Entry Methods - newser.com
Market reaction to Cingulate Inc.’s recent newsDividend Hike & Consistent Income Trade Ideas - newser.com
Is Cingulate Inc. a candidate for recovery playInsider Selling & Weekly Chart Analysis and Guides - newser.com
Cingulate Inc. stock retracement – recovery analysisTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
What does recent volatility data suggest for Cingulate Inc.Trade Analysis Report & Verified Swing Trading Watchlist - newser.com
Using flow based indicators on Cingulate Inc.July 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
Cingulate Inc Azioni (CING) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):